Evidence map›Paper›PMID 38376745›Full record

ReviewCurrent cardiology reports2024

The Global Epidemic of Metabolic Fatty Liver Disease.

Ethan C Z Lee, Vickram V Anand, Alex C Razavi, Pamela L Alebna, Mark D Muthiah, Mohammad S Siddiqui, Nicholas W S Chew, Anurag Mehta

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current cardiology reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 2 pooled it
17.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 2 syntheses or guidelines pooled it, 34 citations in OpenAlex.

  1. Pooled it
  2. Sex differences in survival following acute coronary syndrome with and without standard modifiable risk factors.Clinical research in cardiology : official journal of the German Cardiac Society · 2025
    Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. The E3 Ligase RNF8 Promotes Ubiquitination and Degradation of ChREBPα During Liver Stress Response.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 2 countries.

Ethan C Z Lee *Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore.
Vickram V Anand *Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore.
Alex C RazaviDepartment of Medicine, Division of Cardiology, Emory University School of Medicine, Atlanta, GA, USA.
Pamela L AlebnaVCU Health Pauley Heart Center, Virginia Commonwealth University School of Medicine, 1200 East Broad Street, PO Box 980036, Richmond, VA, 23298, USA.
Mark D MuthiahDivision of Gastroenterology & Hepatology, Department of Medicine, National University Hospital, Singapore, Singapore.
Mohammad S SiddiquiStravitz-Sanyal Institute of Liver Disease and Metabolic Health, Virginia Commonwealth University School of Medicine, Richmond, VA, USA.
Nicholas W S ChewDepartment of Cardiology, National University Heart Centre, National University Health System, Singapore, Singapore.
Anurag MehtaVCU Health Pauley Heart Center, Virginia Commonwealth University School of Medicine, 1200 East Broad Street, PO Box 980036, Richmond, VA, 23298, USA. anurag.mehta@vcuhealth.org.
Virginia Commonwealth University · USNanyang Technological University · SGEmory University · USNational University Health System · SGNational University Hospital · SG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewThe objective of this manuscript is to examine the current literature on the epidemiology of metabolic dysfunction-associated steatotic liver disease (MASLD), its correlation with cardiovascular disease (CVD) outcomes, as well as to evaluate the update in nomenclature from non-alcoholic liver disease (NAFLD). RECENT

findingsThe update of diagnostic criteria from NAFLD to MASLD reduces the stigma associated with alcohol consumption and poor health choices. It also shines a light on the crucial role of cardiometabolic risk factors in disease pathophysiology. The incidence and prevalence of MASLD are projected to increase significantly in the future as the population burden of cardiometabolic risk factors rises. MASLD is also a potent risk factor for developing CVD that should be tackled by using a multi-disciplinary team with a holistic approach. As the new nomenclature for metabolic liver disease is adopted on a global scale, more research is needed to investigate the applicability of findings from previous trials focusing on NAFLD. It is anticipated that the epidemic of MASLD will continue to increase globally, hence the urgent need for therapeutic approaches to reverse this trend.

Indexed as

Cardiovascular DiseasesNon-alcoholic Fatty Liver DiseaseAlcohol DrinkingHumansRisk FactorsCardiometabolic diseaseCardiovascular diseaseMetabolic-associated fatty liver diseaseMetabolic dysfunction-associated steatotic liver diseaseNon-alcoholic fatty liver disease

Identifiers

PMID38376745
OpenAlexW4391962326

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.